Articles

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

Formerly Department of Haematology, Cardiff University School of Medicine, UK
Department of Haematology, Nottingham University Hospital NHS Trust, UK
Department of Haematology, University Hospital of Wales, Cardiff, UK
University College, London Cancer Institute, UK
Department of Haematology, University Hospital of Wales, Cardiff, UK
Department of Haematology, Rigshospitalet, Copenhagen, Denmark
Department of Haematology, Auckland City Hospital, New Zealand
Centre for Trials Research, Cardiff University School of Medicine, UK
Department of Haematology, Blackpool Victoria Hospital, UK
Department of Haematology, Royal Liverpool University Hospital, UK
Department of Haematology, Royal Liverpool University Hospital, UK
Department of Haematology, Nottingham University Hospital NHS Trust, UK
Vol. 103 No. 10 (2018): October, 2018 https://doi.org/10.3324/haematol.2018.189514